Skip to main content
Retour
Watch Compare

Sigyn Therapeutics, Inc.

Qualité des données : 83%
SIGY
OTC Manufacturing Measuring & Analyzing Instruments
0,03 €
▲ 0,01 € (36,00%)
Cap. Boursière: 54 582,0
Prix
0,03 €
Cap. Boursière
54 582,0
Fourchette du Jour
0,02 € — 0,03 €
Fourchette 52 Semaines
0,01 € — 5,00 €
Volume
111 291
Ouverture 0,03 €
Moyenne 50J / 200J
0,29 €
88,35% below
Moyenne 50J / 200J
1,93 €
98,24% below

Quick Summary

Points Clés

Negative free cash flow of -936 426,0

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,02
Interest CoverageN/A

Valorisation

PE (TTM)
-0,02
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E 0,0 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -3,22 M
ROE N/A ROA -3438,93%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -936 426,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,02
Interest Coverage N/A Asset Turnover N/A
Working Capital -3,90 M Tangible Book Value -5,92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,02 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1715,63%
Market Cap 54 582,0 Enterprise Value 3,82 M
Per Share
EPS (Diluted TTM) -1,93 Revenue / Share N/A
FCF / Share -0,58 OCF / Share -0,58
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 29,07%
SBC-Adj. FCF -1,12 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue — — — — —
Net Income -3,34 M -4,15 M -2,93 M -3,00 M -1,26 M
EPS (Diluted) -2,51 -3,77 — — —
Gross Profit — — — — —
Operating Income -2,52 M -2,46 M -2,15 M -2,01 M -916 434,0
EBITDA — — — — —
R&D Expenses 773 279,0 798 165,0 657 657,0 734 014,0 27 456,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 30 800,0 30 800,0 343 156,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 213 719,0 321 806,0 332 879,0 710 259,0 694 082,0
Total Liabilities 4,67 M 3,73 M 2,24 M 974 843,0 594 903,0
Shareholders' Equity -4,46 M -3,41 M -1,90 M -264 584,0 99 179,0
Total Debt 2,20 M 2,51 M 2,28 M — —
Cash & Equivalents 12 144,0 11 690,0 8 356,0 340 956,0 84 402,0
Current Assets 21 244,0 118 063,0 70 298,0 393 031,0 670 449,0
Current Liabilities 4,61 M 3,61 M 2,05 M 734 218,0 594 903,0